LabRoots is pleased to announce the 1st Annual Opioid Crisis Virtual Event taking place on November 5th, 2020. The Opioid epidemic has been called the worst drug crisis in American history. Join us as we discuss and exchange thoughts on the rise, spread, and control of Opioids.
Opioids are chemicals that bind to receptors in the brain and body associated with pain, reward, and addictive behaviors. Opioid medications are used by healthcare providers to relieve pain that cannot be treated with less powerful drugs. Common opioids include heroin and narcotic medications such as oxycodone, buprenorphine, morphine, codeine, methadone, and fentanyl. Opioid-related disorders are associated with overuse, misuse, and dependence on these drugs, and they include opioid-use disorder, opioid intoxication, and opioid withdrawal.
This years event will include the following tracks:
Our virtual conference allows you to participate in a global setting with no travel or cost to you. The event will remain open 6 months from the date of the live event. The webinars will be available for unlimited on-demand viewing. This virtual conference also offers increased reach for the global microbiology community with a high degree of interaction through live-streaming video and chat sessions.
This event will be produced on our robust platform, allowing you to watch, learn and connect seamlessly across all desktop or mobile devices. Equipped with gamification and point system, you can now move around the entire event, earning points for a chance to win one of LabRoots' most popular T-shirts.
Call for Posters — Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Plan now to have your poster included in the 2020 Opioid Crisis Virtual Event. Submission is free. Submit your abstract here.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this event, you can earn 1 Continuing Education credit per presentation for a maximum of 14 credits.
Use #LRopioids to follow the conversation!
POSTER SUBMISSION GUIDELINES
Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Posters should be submitted as a PowerPoint file. Presentations should incorporate illustrative materials such as tables, graphs, photographs, and large-print text. This content is not peer-reviewed. Submission is free.
SUBMIT YOUR ABSTRACT
Enter the following information to this Submission Form:
All submitted abstracts will be reviewed and decisions regarding acceptance will be made as abstracts are received. You will be notified within one week of receipt about acceptance. Further details and registration materials will be provided at that time. You do not have to be present in order to have a poster displayed. Only those abstracts approved by LabRoots may display posters at this event.
If accepted, you will also have the opportunity to record a 3-5 minute summary video for each poster. LabRoots will work with each individual to create these videos. Video links and email contact information will be included on each poster displayed.
Questions? Email Posters@LabRoots.com
Rebecca G. Baker, Ph.D., is the director of the Helping to End Addiction Long-termSM Initiative, or NIH HEAL InitiativeSM, in the Office of the Director, NIH. Dr. Baker helped develop the NIH HEAL Initiative and leads coordination of HEAL programmatic activities between the Office of the Director and relevant Institutes and Centers (ICs), NIH HEAL Initiative staff, and governance committees. She also provides expert advice to and represents the NIH Director on initiative-related activities, including interagency efforts and partnerships in pain and opioid research and policy. Prior to holding this position, Dr. Baker was special assistant to the NIH Director, working directly with NIH leadership to develop new scientific initiatives, and analyze scientific, legislative, communications, and policy issues. Previously, she worked as a postdoctoral scientist using next-generation DNA sequencing to identify novel disease-causing genes in patients with rare immunological diseases. She earned her Ph.D. from the University of Pennsylvania and her bachelor's degree from Cornell University.
Jennifer Ball is an associate professor of pharmacy practice at South Dakota State University. She practices in ambulatory care with a focus in substance use disorders and women's health at the Center for Family Medicine as faculty within the Sioux Falls Family Medicine Residency Program and Pierre Rural Family Medicine Residency Program. Within her clinical and education role, Jennifer practices as part of an interdisciplinary substance use disorders treatment team and provides statewide education as a hub expert in Avera Project ECHO: Substance Use, Mental Health, and MAT. Her role in substance use disorders training has awarded her several State Opioid Response (SOR) and Rural Communities Opioid Response Program (RCORP) grants to expand treatment, healthcare professional training, and networking across the state of South Dakota.
Current position. Professor of Psychobiology, Harvard Medical School (34 years) with office based at McLean Hospital Belmont, MA and cross-appointment at the Massachusetts General Hospital. Educated at McGill University, Montreal; post-doctoral fellow MIT.
Translational Research. Addictive and therapeutic drugs: behavioral, molecular responses. Drug discovery. Novel brain probes, candidate therapeutics for neuropsychiatric disorders
Authorship. Author of over 200 scientific manuscripts, articles, book chapters, co-editor of books “The Cell Biology of Addiction”, “Effects of Drug Abuse on the Human Nervous System”, “Imaging of the Human Brain in Health and Disease”.
Inventions. 19 U.S. and 27 international patents, with collaborators.
Government service and public policy. Numerous NIH committees and other advisory boards
Educator, Public Service. Over 300 presentations to students, public, professionals
Her experiences in research, brain biology, education, government and public service offer her a unique perspective on public policy, brain science and public education.
A New England native, Joseph DeLuca was born and raised in Lowell, Massachusetts, attended high school in Nashua, NH, and received a Bachelor's of Science from Syracuse University in 1993. His police career started over twenty years ago. His jurisdictions included sea (a stint with New Hampshire's Marine Patrol assigned him to Rockingham County and the Seacoast), land (hundreds of thousands of miles of road patrol), and air (licensed with the Federal Aviation Administration as a commercial sUAS pilot). His resume includes TASER instructor, ASP instructor, Field Training Officer, Drug Recognition Expert, DARE Instructor, Central New Hampshire Special Operations Unit Operator/ Grenadier, and School Resource Officer, among other duties. He has worked at the Lincoln (NH) Police Department for over fifteen years, and has held the rank of patrol sergeant for the past nine. An amateur musician, Sgt. DeLuca looks forward to the New Hampshire Highland Games, hosted at Loon Mountain in Lincoln. He plays the bagpipes with the New Hampshire Police Association Pipes & Drums and the Pipes & Drums of NHSCOT.
Dr. Franko is a 2011 graduate of the Philadelphia College of Pharmacy. He completed a PGY1 residency at the Wilkes-Barre Veteran's Affairs Medical Center. After residency he developed the first pharmacist run medication therapy management clinic focused on chronic non-cancer pain in the region at Geisinger Medical Center in Danville, PA. Dr. Franko joined the faculty at Wilkes University in 2013 with a focus in pain management and substance use disorder. While at Wilkes Dr. Franko authored several papers on innovative education methodologies for pain management, opioid use, and pharmacist involvement with naloxone. He has developed a pain and addiction elective course, and a substance use disorder practice lab focused on naloxone administration and SBIRT. He is the advisor for the Wilkes chapter of Rho Chi, Generation Rx, and the faculty liaison for SARPH, the pharmacist recovery program for Pennsylvania. He has presented several hours of continuing education on pain and substance use disorder issues on the state and national level. Dr. Franko serves on several local, state and national committees aimed to enhance professional and public education on substance use disorder. Current positions include Coordinator Elect for the Pain, Palliative Care, and Addiction Special Interest Group for the American Pharmacists Association, Region Two Councilor for Rho Chi, and President-Elect of the Pennsylvania Pharmacists Association. Dr. Franko was named a Cardinal Health Generation Rx Champion for Pennsylvania in 2018 and was the lead author for the Pennsylvania Controlled Substance Dispensing Guidelines.
Dr. Linda Porter directs the National Institutes of Health's Office of Pain Policy and Planning. She holds a bachelor's degree in Physical Therapy from McGill University and a Ph.D. in Neuroscience from Boston University. Dr. Porter trained in neurophysiology at Rockefeller University and then served on the faculty of the Uniformed Services University, where she directed a research program on sensory-motor integration. Dr. Porter joined the NIH in 2003 where her role includes coordinating activities of the NIH Pain Consortium and the Interagency Pain Research Coordinating Committee, whose missions respectively, are to advance the trans-NIH and interagency pain research agenda. She co-chaired the development of the National Pain Strategy and the Federal Pain Research Strategy and now is involved with the NIH HEAL (Helping End Addiction Long-term) initiative. Dr. Porter has been recognized for her work through the President's Award from the American Academy of Pain Management, NIH Director's Awards, and the Emma and John Bonica Public Service Award from the American Pain Society.
Jack B. Stein, Ph.D. has over two decades of professional experience in leading national drug and HIV-related research, practice, and policy. He first joined NIDA as the OSPC Deputy Director, and later as the Deputy Director for the Division of Epidemiology, Services and Prevention Research. He then left NIDA to become Director of the Division of Services Improvement, Center for Substance Abuse Treatment at the Substance Abuse and Mental Health Services Administration. Immediately prior to rejoining NIDA, Dr. Stein served as the Chief of the Prevention Branch, Office of Demand Reduction, at the White House Office of National Drug Control Policy. Dr. Stein has authored numerous articles, book chapters, and reports on HIV prevention and substance use services. He is a graduate of Union College, where he earned a bachelor of science in biology. He holds a master's degree in social work from New York University and a doctoral degree in health services from Walden University.
Dr. Glenn Sterner is an Assistant Professor of Criminal Justice at The Pennsylvania State University, Abington Campus. He serves as the coordinator of the Criminal Justice Research Center's Greater Philadelphia Office for the University. As an expert on the opioid epidemic, he sits on the Opioid Overdose Task Force for the State of Pennsylvania. He is also a founding member of the Penn State Consortium to Combat Substance Abuse advisory board. He serves as a faculty fellow of the Penn State University Administrative Data Accelerator. He is the founder of the Share Your Opioid Story initiative, found at www.shareyouropioidstory.com. His main research agenda is focused on the application of social network analysis in understanding illicit, illegal, and covert networks, and he is experienced with both quantitative and qualitative research methodologies. Dr. Sterner has been awarded over $6.7 Million in local, state, and federal grants to study and address the opioid epidemic, including funding from the National Institute of Justice, Department of Justice, and the Substance Abuse and Mental Health Services Administration (SAMHSA). His work includes the examination of opioid abuse networks, illegal opiate distribution, networks of legitimate opioid distributors and overdose deaths, hot spots of opioid availability, intelligence-based interventions in rural areas, and stigma associated with opioid and other substance use disorders. Dr. Sterner has presented his work locally, nationally, and internationally to organizations including opioid treatment and support organizations, Centre County HOPE, The Bucks County Together We Can Convention, Penn State Extension Annual Conference, The Wolf Administration's Opioid Command Center, Georgia Pacific Company, The Federal Reserve Bank of Philadelphia, The American Society of Criminology, The Stockholm Criminology Symposium, and the International Network of Social Network Analysts. His writings on this topic have been featured by the Department of Justice, The Hill, The Independence Blue Cross Foundation, and The National Prevention Science Coalition for Improving Lives, and peer reviewed journals including Substance Use and Misuse. Dr. Sterner collaborates extensively with law enforcement agencies on the local, state, and federal level in his work to address the opioid crisis and other substance use issues. He has several active grants with the Pennsylvania State Police, and partners with local district attorneys, coroners, and police departments. Within the Pennsylvania State Police, he regularly works with individuals in the Pennsylvania Criminal Intelligence Center (PaCIC), the data fusion center at State Police Headquarters in Harrisburg. He has relationships within the Pennsylvania Attorney General's Bureau of Narcotics Division, the Liberty Mid-Atlantic High Intensity Drug Trafficking Area (HIDTA), and the Federal Bureau of Investigation (FBI), whom he relies on for support of his research. Dr. Sterner has excellent relationships with the National Institute of Justice, and has been successful in receiving over $2.2M in grant funding across three projects to address drug trafficking and markets, specifically with an emphasis on opioids. Dr. Sterner is dedicated to a collaborative criminal justice approach to addressing key issues associated with drug markets, sales, trafficking, and use, and he actively works across agencies and organizations to promote this ethos in his research and outreach endeavors. Dr. Sterner has worked extensively with the Independence Blue Cross Foundation, the Department of Drug and Alcohol Programs, and Mental Health Partnerships to address stigma associated with the opioid epidemic, coordinating the Share Your Opioid Story initiative, which has helped to highlight the depth and breadth of this issue in our communities through qualitative story telling. Through this work, he has provided the opportunity to open up the conversation on stigma, helping to ensure that all individuals associated with the opioid epidemic are supported in our communities, rural to urban. This partnership between Penn State University, Independence Blue Cross Foundation, the Pennsylvania Department of Drug and Alcohol Programs, and Mental Health Partnerships has been recognized by the Pennsylvania Business Journal through their Faces of Philanthropy. For his work on the opioid epidemic, Dr. Sterner has been recognized by the Independence Blue Cross Foundation as a Future Leader of Community Health. He received the 2019 Penn State Community Engagement and Scholarship Award for the impact the Share Your Opioid Story Initiative is having in our communities, and in 2020 was recognized by the University for his engaged scholarly activity. In addition to his extensive work on the opioid epidemic, he is also actively engaged in research on the networks of human sex trafficking. He is a dedicated scholar in community engagement. He is also actively engaged in research to improve learning for students in higher education. He received his PhD from The Pennsylvania State University in Rural Sociology, and an M.A. and B.S. from Michigan State University.
Alan H.B. Wu, Ph.D., DABACC, is Chief of Clinical Chemistry and Toxicology at San Francisco General Hospital Professor of Laboratory Medicine, University of California, San Francisco, and medical director for the Pharmacogenomics Laboratory. He received B.S. degrees in chemistry and biology at Purdue University, West Lafayette, Indiana, and a Ph.D. degree in analytical chemistry at the University of Illinois, Champaign-Urbana, Illinois. He completed a postdoctoral fellowship in clinical chemistry at Hartford Hospital. He is certified by the American Board of Clinical Chemistry in Clinical Chemistry and Toxicological Chemistry. His research interests include pharmacogenomics, clinical toxicology, cardiac biomarkers, and point-of-care testing. Dr. Wu has over 400 publications in peer-reviewed journals. He has also written five paperback books consisting of short stories designed to promote the value of the clinical laboratory and pharmacogenomics to the general public.
YOU WILL STAND OUT TO EMPLOYERS. As a top-ranked, regionally accredited institution, known for its interdisciplinary approach to applied education, Drexel consistently gets high marks from employers for its online degree and certificate programs. In fact, we have made it our ...See more See less
The speakers below have been approved for Continuing Education Credits. To redeem your credits, locate the presentation you watched and click on the CE buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here
|Operating System||Internet Explorer||Firefox||Chrome||Safari|
|Windows 7||IE8+||FF10+||Chrome15+||Windows 8||IE10||FF10+||Chrome15+|
|Mac OS X||FF10+||Chrome15+||Safari5.1+|
- For viewing Webinars:
- For viewing Virtual Events
Research And Development
Labroots Registration (Also interested in)13%
WAVE Newsletter Promotion4%
Social Media Promotions3%
Trending Newsletter Promotion1%
Medical Laboratory Technician11%
Clinical Laboratory Scientist5%
Life Science Company1%